Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

Sparsentan (SPAR) as First-Line Treatment of Incident Patients with IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial

Page 1 / 1 100%
Loading...